Ro52, Ro60 and La IgG autoantibody levels and Ro52 IgG subclass profiles longitudinally throughout pregnancy in congenital heart block risk pregnancies

Lupus

Volumn 15, Issue 6, 2006, Pages 346-353

  Strandberg, L ^a   Salomonsson, S ^a   Bremme, K ^a   Sonesson, S E ^a   Wahren Herlenius, Marie ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Autoantibodies; Congenital heart block; La; Ro52; Ro60

Indexed keywords

ANTIBODY RO52; ANTIBODY RO60; AUTOANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; LA ANTIBODY; RECOMBINANT ANTIGEN; RECOMBINANT PROTEIN; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY SPECIFICITY; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONGENITAL HEART BLOCK; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FETUS; HIGH RISK PREGNANCY; HUMAN; NEWBORN; PREGNANCY; PRIORITY JOURNAL; RHEUMATIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANTIBODIES, ANTINUCLEAR; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIGENS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HEART BLOCK; HUMANS; IMMUNITY, MATERNALLY-ACQUIRED; IMMUNOGLOBULIN G; INFANT, NEWBORN; LUPUS ERYTHEMATOSUS, SYSTEMIC; MATERNAL-FETAL EXCHANGE; MIXED CONNECTIVE TISSUE DISEASE; PREGNANCY; PREGNANCY COMPLICATIONS; RIBONUCLEOPROTEINS; RISK; RNA, SMALL CYTOPLASMIC; SJOGREN'S SYNDROME;

EID: 33745860410     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203306lu2309oa     Document Type: Article

References (38)

1. Buyon JP, Hiebert R, Copel J et al. Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol 1998; 31: 1658-1666.
2. Brucato A, Frassi M, Franceschini F et al. Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women. Arthritis Rheum 2001; 44: 1832-1835.
3. Waltuck J, Buyon JP. Autoantibody-associated congenital heart block: outcome in mothers and children. Ann Intern Med 1994; 120: 544-551.
4. Julkunen H, Eronen M. The rate of recurrence of isolated congenital heart block: a population-based study. Arthritis Rheum 2001; 44: 487-488.
5. Solomon DG, Rupel A, Buyon JP. Birth order, gender and recurrence rate in autoantibody-associated congenital heart block: implications for pathogenesis and family counseling. Lupus 2003; 12: 646-647.
6. Eronen M, Siren MK, Ekblad H et al. Short- and long-term outcome of children with congenital complete heart block diagnosed in utero or as a newborn. Pediatrics 2000; 106: 86-91.
7. Salomonsson S, Dorner T, Theander E et al. A serologic marker for fetal risk of congenital heart block. Arthritis Rheum 2002; 46: 1233-1241.
8. Salomonsson S, Ottosson L, Safsten P et al. Cloning and characterization of two human Ro52-specific monoclonal autoantibodies directed towards a domain associated with congenital heart block. J Autoimmun 2004; 22: 167-177.
9. Salomonsson S, Sonesson SE, Ottosson L et al. Ro/SSA autoantibodies directly bind cardiomyocytes, disturb calcium homeostasis, and mediate congenital heart block. J Exp Med 2005; 201: 11-17.
10. Garcia S, Nascimento JH, Bonfa E et al. Cellular mechanism of the conduction abnormalities induced by serum from anti-Ro/SSA-positive patients in rabbit hearts. J Clin Invest 1994; 93: 718-724.
11. Boutjdir M, Chen L, Zhang ZH et al. Arrhythmogenicity of IgG and anti-52-kD SSA/Ro affinity-purified antibodies from mothers of children with congenital heart block. Circ Res 1997; 80: 354-362.
12. Dörner T, Chaoui R, Feist E et al. Significantly increased maternal and fetal IgG autoantibody levels to 52 kD Ro (SS-A) and La(SS-B) in complete congenital heart block. J Autoimmun 1995; 8: 675-684.
13. Sonesson SE, Salomonsson S, Jacobson L-A, Bremme K, Wahren-Herlenius M. Signs of first degree heart block occurs in one third of fetuses of pregnant women with anti-SSA/Ro52 antibodies. Arthritis and Rheumatism 2004; 50: 1253-1261.
14. Wahren M, Tengnér P, Gunnarsson I et al. Autoantibody levels to Ro/SS-A and La/SS-B in patients with systemic lupus erythematosus and Sjögren's syndrome. J Autoimmun 1998; 11: 29-38.
15. St Clair EW, Burch JA Jr, Ward MM, Keene JD, Pisetsky DS. Temporal correlation of antibody responses to different epitopes of the human La autoantigen. J Clin Invest 1990; 85: 515-521.
16. Meilof JF, Veldhoven CH, Swaak AJ, Smeenk RJ. Production of anti-Ro/SS-A and anti-La/SS-B autoantibodies is closely coordinated in systemic lupus erythematosus and independent of anti-dsDNA production. J Autoimmun 1997; 10: 67-75.
17. Praprotnik S, Bozic B, Kveder T, Rozman B. Fluctuation of anti-Ro/SS-A antibody levels in patients with systemic lupus erythematosus and Sjogren's syndrome: a prospective study. Clin Exp Rheumatol 1999; 17: 63-68.
18. Vitali C, Bombardieri S, Jonsson R et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 554-558.
19. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
20. Alarcon-Segovia D, Cardiel MH. Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients. J Rheumatol 1989; 16: 328-334.
21. Wilson WA, Gharavi AE, Koike T et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309-1311.
22. Elagib KEE, Tengnér P, Levi M et al. Immunoglobulin variable genes and epitope recognition of human monoclonal anti-Ro 52-kd in primary Sjogren's syndrome. Arthritis Rheum 1999; 42: 2471-2478.
23. Hinkula J, Ball JM, Löfgren S, Estes M, Svensson L. Antibody prevalence and immunoglobulin IgG subclass pattern to Norwalk virus in Sweden. J Med Virol 1995; 47: 52-57.
24. Sundqvist V-A, Linde A, Kurth R et al. Restriced IgG subclass responses to HTLV-III/LAV and to cytomegalovirus in patients with AIDS and lymphadenopathy syndrome. J Inf Dis 1986; 153: 970-973.
25. Khirwadkar MA, Kher JR. Study of serum immunoglobulins in normal pregnancy. Indian J Physiol Pharmacol 1991; 35: 69-70.
26. Amino N, Tanizawa O, Miyai K et al. Changes of serum immunoglobulins IgG, IgA, IgM, and IgE during pregnancy. Obstet Gynecol 1978; 52: 415-420.
27. Ailus K. A follow-up study of immunolglobulin levels and autoantibodies in an unselected pregnant population. Am J Reprod Immunol 1994; 31: 189-196.
28. Marolis GB, Buckley RH, Younger JB. Serum immunogbulin cocentrations during normal pregnancy. Am J Obstet Gynecol 1971; 109: 971-976.
29. Thellin O, Heinen E. Pregnancy and the immune system: between tolerance and rejection. Toxicology 2003; 185: 179-184.
30. Derksen RH, Meilof JF. Anti-Ro/SS-A and anti-La/SS-B autoantibody levels in relation to systemic lupus erythematosus disease activity and congenital heart block. A longitudinal study comprising two consecutive pregnancies in a patient with systemic lupus erythematosus. Arthritis Rheum 1992; 35: 953-959.
31. Lieu T-S, Reimer CB, Sontheimer RD. Immunoglobulin class and subclass profile of the Ro/SS-A autoantibody response. J Invest Dermatol 1988; 90: 158-164.
32. Elenitsas R, Abell E, Lee Y-Y, Huang J, Deng J-S. Comparison of IgG subclass antibodies in patients with systemic lupus erythematosus and aubacute lupus erythematosus. J Dermatol Sci 1990; 1: 207-216.
33. Pearce DC, Yount WJ, Eisenberg RA. Subclass restriction of anti-SS-B (La) autoantibodies. Clin Immunol Immunopathol 1986; 38: 111-119.
34. Wahren M, Ringertz NR, Pettersson I. IgM and IgG subclass distribution of human anti-Ro/SSA 60 kDa autoantibodies. Scand J Immunol 1994; 39: 179-183.
35. Simister NE. Placental transport of immunoglobulin G. Vaccine 2003; 21: 3365-3369.
36. Tseng CE, Caldwell K, Feit S, Chan EK, Buyon JP. Subclass distribution of maternal and neonatal anti-Ro(SSA) and La(SSB) antibodies in congenital heart block. J Rheumatol 1996; 23: 925-932.
37. Kaaja R, Julkunen H. Prevention of reocurrence of congential heart block with intravenous immunoglobulin and corticosteroid therapy. Arthritis Rheum 2003; 48: 280-281.
38. Tran HB, Cavill D, Buyon JP, Gordon TP. Intravenous immunoglobulin and placental transport of anti-Ro/La antibodies. Arthritis Rheum 2004; 50: 337-338.